VYUHPHARMA

Highlights from the Week of 1st January 2026 to 12th January 2026

台灣神隆股份有限公司
ScinoPharm Taiwan, Ltd.

FDA approves ScinoPharm's injectable GLATIRAMER ACETATE for multiple sclerosis

(FDA, Approval)

Biocon

Biocon Pharma receives FDA approval for EVEROLIMUS tablets for oral suspension, indicated for the treatment of certain types of tumors and tuberous sclerosis complex

(FDA, Approval)

GSK

European Commission approves GSK's SHINGRIX recombinant zoster vaccine in a prefilled syringe presentation

(EU, Approval)

VYUHPHARMA

Highlights from the Week of 1st January 2026 to 12th January 2026

Complement Therapeutics gains Fast Track designation for its gene therapy CTX001, to treat geographic atrophy secondary to age-related macular degeneration

(FDA, Fast Track)

Oculis gains FDA Breakthrough Therapy designation for Privosegtor to treat patients with optic neuritis

(FDA, Breakthrough Therapy)

FDA grants Orphan Drug designation to Arbele's ARB1002, an anti-CDH17 antibody drug conjugate for pancreatic cancer treatment

(FDA, Orphan Drug)

VYUHPHARMA

Highlights from the Week of 1st January 2026 to 12th January 2026

sanofi

Sanofi's sBLA for Tzield in children aged one to seven with stage 2 type 1 diabetes receives FDA priority review

(FDA, Priority Review)

vera therapeutics™

Vera Therapeutics gains priority review for its BLA atacicept in IgA nephropathy, with a PDUFA target action date of June 3, 2026

(FDA, Priority Review)

novo nordisk®

Novo Nordisk makes the WEGOVY pill available in the US as the first and only oral GLP-1 for adult weight management and cardiovascular risk reduction

(Commercialisation)